Ayodeji A. Asuni
Research Subjects
Research Interests
Ayodeji A. Asuni has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Martin J. Sadowski
New York University School of Medicine, New York, NY USA
2 shared publications - Albert D. Windhorst
Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117, Amsterdam, The Netherlands
1 shared publication - Allal Boutajangout
Center for Cognitive Neurology NYU Grossman School of Medicine New York New York USA
1 shared publication Allan Jensen
Antibody Discovery & Assay Technology
1 shared publication- Allan Jensen
Symphogen, Pederstrupvej 93, DK-2750, Ballerup, Denmark
1 shared publication - Allan Stensballe
Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
1 shared publication
Latest Publications
- Open Access
Highly Sensitive Assays for detection of headache inducing neuropeptides, Pituitary adenylate cyclase-activating polypeptide (PACAP) and Calcitonin gene-related peptide (CGRP)
Background: Migraine is one of the most disabling diseases that continues to pose a significant societal burden. Although there are now treatment options for people with migraine, it remains challenging to identify them as clinical features are diverse and complex, and there are no validated diagnostic or treatment prediction biomarkers. Identification is based on either diagnostic coding or the use of certain acute headache abortive treatments. However, socioeconomic disparities can contribute to under-diagnosis and under-treatment of migraine. Thus, efforts to find biomarkers to identify individuals with migraine and which variables could explain migraine-related chronification and disability are warranted. We aimed to investigate the levels of migraine inducing neuropeptides; calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in peripheral blood samples as potential biomarkers of migraine. Methods: We developed highly sensitive assays for CGRP and PACAP on the MSD S-PLEX assay platform and used them for bioanalysis of preclinical and clinical samples. Wildtype and neuropeptide challenged mice and rats were profiled using the developed assay. To follow-up, commercially obtained plasma samples from healthy controls and migraineurs were initially profiled. Subsequently, we profiled plasma samples from people with migraine (during and after a headache attack and healthy controls. Both MSD S-PLEX assays were transferred to Celerion where they were validated for analysis of clinical samples. Results: Using the highly sensitive PACAP assay, we were able to reliably measure circulating levels of endogenous and administrated PACAP38in mouse and rat plasma. Additionally, using the highly sensitive CGRP assay, we were able to reliably measure circulating levels of endogenous and administrated CGRP in mouse and rat plasma. Furthermore, in the initial human samples, circulating CGRP and PACAP levels were not significantly different in healthy controls compared to people with migraine patients. However, ≥50% people with migraine showed increased circulating CGRP and PACAP levels during their attack period compared to post attack. Overall, people with migraine showed a 3 – 396% increase in one or both neuropeptides during their attack period compared to post attack. Circulating plasma CGRP and PACAP levels in healthy control subjects were consistent with previously measured levels. Conclusion: Our highly sensitive PACAP and CGRP assays were successful in measuring circulating levels of endogenous PACAP38 and CGRP in mouse and rat plasma. Our highly sensitive PACAP and CGRP assays were qualified for measurement of human CGRP and PACAP in healthy control and migraine samples. Plasma CGRP and PACAP levels are elevated in migraineurs during an attack period, and the increased plasma neuropeptide levels during an attack may help the differentiation of migraineurs from non-Migraineurs, or amongst people with migraines to help identify the best treatment for each patient.
Open AccessHighly Sensitive Assays for detection of headache inducing neuropeptides, Pituitary adenylate cyclase-activating polypeptide (PACAP) and Calcitonin gene-related peptide (CGRP)
Background: Migraine is one of the most disabling diseases that continues to pose a significant societal burden. Although there are now treatment options for people with migraine, it remains challenging to identify them as clinical features are diverse and complex, and there are no validated diagnostic or treatment prediction biomarkers. Identification is based on either diagnostic coding or the use of certain acute headache abortive treatments. However, socioeconomic disparities can contribute to under-diagnosis and under-treatment of migraine. Thus, efforts to find biomarkers to identify individuals with migraine and which variables could explain migraine-related chronification and disability are warranted. We aimed to investigate the levels of migraine inducing neuropeptides; calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in peripheral blood samples as potential biomarkers of migraine. Methods: We developed highly sensitive assays for CGRP and PACAP on the MSD S-PLEX assay platform and used them for bioanalysis of preclinical and clinical samples. Wildtype and neuropeptide challenged mice and rats were profiled using the developed assay. To follow-up, commercially obtained plasma samples from healthy controls and migraineurs were initially profiled. Subsequently, we profiled plasma samples from people with migraine (during and after a headache attack and healthy controls. Both MSD S-PLEX assays were transferred to Celerion where they were validated for analysis of clinical samples. Results: Using the highly sensitive PACAP assay, we were able to reliably measure circulating levels of endogenous and administrated PACAP38in mouse and rat plasma. Additionally, using the highly sensitive CGRP assay, we were able to reliably measure circulating levels of endogenous and administrated CGRP in mouse and rat plasma. Furthermore, in the initial human samples, circulating CGRP and PACAP levels were not significantly different in healthy controls compared to people with migraine patients. However, ≥50% people with migraine showed increased circulating CGRP and PACAP levels during their attack period compared to post attack. Overall, people with migraine showed a 3 – 396% increase in one or both neuropeptides during their attack period compared to post attack. Circulating plasma CGRP and PACAP levels in healthy control subjects were consistent with previously measured levels. Conclusion: Our highly sensitive PACAP and CGRP assays were successful in measuring circulating levels of endogenous PACAP38 and CGRP in mouse and rat plasma. Our highly sensitive PACAP and CGRP assays were qualified for measurement of human CGRP and PACAP in healthy control and migraine samples. Plasma CGRP and PACAP levels are elevated in migraineurs during an attack period, and the increased plasma neuropeptide levels during an attack may help the differentiation of migraineurs from non-Migraineurs, or amongst people with migraines to help identify the best treatment for each patient.
- 30 December 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 109, 63-77
Amyloid-β targeting immunisation in aged non-human primate (Microcebus murinus)
- 30 December 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 109, 63-77
Amyloid-β targeting immunisation in aged non-human primate (Microcebus murinus)
- 15 July 2019
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 33 (22) , 1711-1721
Dual strategy for reduced signal‐suppression effects in matrix‐assisted laser desorption/ionization mass spectrometry imaging
Rationale: The molecular complexity of tissue features several signal‐suppression effects which reduce the ionization of analytes significantly and thereby weakens the quality of matrix‐assisted laser desorption/ionization (MALDI) mass spectrometry (MS) imaging (MALDI imaging). We report a novel approach in MALDI imaging by reducing signal‐suppression effects for the analysis of beta‐amyloid (Aβ) plaques, one pathological hallmark of Alzheimer's disease (AD). Methods: We analyzed Aβ proteoforms from postmortem AD brains and brains from transgenic mice (APPPS1‐21) overexpressing familial AD mutations by combining two techniques: (1) laser capture microdissection (LCM) to accumulate Aβ plaques and (2) phosphoric acid (PA) as additive to the super‐2,5‐dihydroxybenzoic acid matrix. Results: LCM and MALDI‐MS enabled tandem mass spectrometric fragmentation of stained Aβ plaques. PA improved the signal‐to‐noise (S/N) ratio, especially of the Aβ1‐42 peptide, by three‐fold compared with the standard matrix additive trifluoroacetic acid. The beneficial effect of the PA matrix additive in MALDI imaging was particularly important for AD brain tissue. We identified several significant differences in Aβ plaque composition from AD compared with APPPS1‐21, underlining the value of reducing signal‐suppressing effects in MALDI imaging. Conclusions: We present a novel strategy for overcoming signal‐suppression effects in MALDI imaging of Aβ proteoforms.
- 15 July 2019
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 33 (22) , 1711-1721
Dual strategy for reduced signal‐suppression effects in matrix‐assisted laser desorption/ionization mass spectrometry imaging
Rationale: The molecular complexity of tissue features several signal‐suppression effects which reduce the ionization of analytes significantly and thereby weakens the quality of matrix‐assisted laser desorption/ionization (MALDI) mass spectrometry (MS) imaging (MALDI imaging). We report a novel approach in MALDI imaging by reducing signal‐suppression effects for the analysis of beta‐amyloid (Aβ) plaques, one pathological hallmark of Alzheimer's disease (AD). Methods: We analyzed Aβ proteoforms from postmortem AD brains and brains from transgenic mice (APPPS1‐21) overexpressing familial AD mutations by combining two techniques: (1) laser capture microdissection (LCM) to accumulate Aβ plaques and (2) phosphoric acid (PA) as additive to the super‐2,5‐dihydroxybenzoic acid matrix. Results: LCM and MALDI‐MS enabled tandem mass spectrometric fragmentation of stained Aβ plaques. PA improved the signal‐to‐noise (S/N) ratio, especially of the Aβ1‐42 peptide, by three‐fold compared with the standard matrix additive trifluoroacetic acid. The beneficial effect of the PA matrix additive in MALDI imaging was particularly important for AD brain tissue. We identified several significant differences in Aβ plaque composition from AD compared with APPPS1‐21, underlining the value of reducing signal‐suppressing effects in MALDI imaging. Conclusions: We present a novel strategy for overcoming signal‐suppression effects in MALDI imaging of Aβ proteoforms.
- 1 November 2015
- Published by Elsevier in Neurochemistry International
- Vol. 90, 152-165
Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo
- 1 November 2015
- Published by Elsevier in Neurochemistry International
- Vol. 90, 152-165
Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo
- 28 January 2013
- Published by Elsevier in Neuroscience Letters
- Vol. 538, 26-31
Differential molecular chaperone response associated with various mouse adapted scrapie strains
- 28 January 2013
- Published by Elsevier in Neuroscience Letters
- Vol. 538, 26-31
Differential molecular chaperone response associated with various mouse adapted scrapie strains
- 22 March 2010
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 38 (2) , 545-551
Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease
Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD (Alzheimer's disease), where it is associated with disrupted axonal transport and probably causes synaptic dysfunction. Although less well studied, hyperphosphorylation has been observed in prion disease. We have investigated the expression of hyperphosphorylated tau in the hippocampus of mice infected with the ME7 prion agent. In ME7-infected animals, there is a selective loss of CA1 synapse, first discernable at 13 weeks of disease. There is a potential that dysfunctional axonal transport contributes to this synaptopathy. Thus investigating hyperphosphorylated tau that is dysfunctional in AD could illuminate whether and how they are significant in prion disease. We observed no differences in the levels of phosphorylated tau (using MC1, PHF-1 and CP13 antibodies) in detergent-soluble and detergent-insoluble fractions extracted from ME7- and NBH- (normal brain homogenate) treated animals across disease. In contrast, we observed an increase in phospho-tau staining for several epitopes using immunohistochemistry in ME7-infected hippocampal sections. Although the changes were not of the magnitude seen in AD tissue, clear differences for several phospho-tau species were seen in the CA1 and CA3 of ME7-treated animals (pSer199−202>pSer214>PHF-1 antibody). Temporally, these changes were restricted to animals at 20 weeks and none of the disease-related staining was associated with the axons or dendrites that hold CA1 synapses. These findings suggest that phosphorylation of tau at the epitopes examined does not underpin the early synaptic dysfunction. These data suggest that the changes in tau phosphorylation recorded here and observed by others relate to end-stage prion pathology when early dysfunctions have progressed to overt neuronal loss.
- 22 March 2010
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 38 (2) , 545-551
Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease
Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD (Alzheimer's disease), where it is associated with disrupted axonal transport and probably causes synaptic dysfunction. Although less well studied, hyperphosphorylation has been observed in prion disease. We have investigated the expression of hyperphosphorylated tau in the hippocampus of mice infected with the ME7 prion agent. In ME7-infected animals, there is a selective loss of CA1 synapse, first discernable at 13 weeks of disease. There is a potential that dysfunctional axonal transport contributes to this synaptopathy. Thus investigating hyperphosphorylated tau that is dysfunctional in AD could illuminate whether and how they are significant in prion disease. We observed no differences in the levels of phosphorylated tau (using MC1, PHF-1 and CP13 antibodies) in detergent-soluble and detergent-insoluble fractions extracted from ME7- and NBH- (normal brain homogenate) treated animals across disease. In contrast, we observed an increase in phospho-tau staining for several epitopes using immunohistochemistry in ME7-infected hippocampal sections. Although the changes were not of the magnitude seen in AD tissue, clear differences for several phospho-tau species were seen in the CA1 and CA3 of ME7-treated animals (pSer199−202>pSer214>PHF-1 antibody). Temporally, these changes were restricted to animals at 20 weeks and none of the disease-related staining was associated with the axons or dendrites that hold CA1 synapses. These findings suggest that phosphorylation of tau at the epitopes examined does not underpin the early synaptic dysfunction. These data suggest that the changes in tau phosphorylation recorded here and observed by others relate to end-stage prion pathology when early dysfunctions have progressed to overt neuronal loss.
- 1 February 2010
- Published by Elsevier in Neuroscience
- Vol. 165 (3) , 662-674
Alpha-synuclein deficiency in the C57BL/6JOlaHsd strain does not modify disease progression in the ME7-model of prion disease
- 1 February 2010
- Published by Elsevier in Neuroscience
- Vol. 165 (3) , 662-674
Alpha-synuclein deficiency in the C57BL/6JOlaHsd strain does not modify disease progression in the ME7-model of prion disease